Testing a drug called orelabrutinib for lupus symptoms in adults
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 2 trial studies whether orelabrutinib can improve systemic lupus erythematosus (SLE) and check its safety. It may help people with active lupus who are already on stable lupus medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent and understand the study before joining.
- You’re age 18 to 75, and you have a confirmed SLE diagnosis for at least 6 months.
- Your lupus activity score at screening must be high (SLEDAI-2K of 8 or more).
- You must be on stable standard lupus treatment for at least 30 days before the first dose (such as steroid pills/shot and/or anti-malarial and/or immunosuppressing medicines).
- Your blood tests must show lupus-related antibodies (anti-dsDNA and/or ANA and/or anti-Smith) higher than normal.
- If you can become pregnant: you must use a highly effective birth-control method plus an added barrier method during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests two new oral medications (ICP-248 and Orelabrutinib) together as a first treatment for people with CLL or SLL. The goal is to see if this combination works better than current options and is safe for newly diagnosed patients.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests an oral targeted therapy (orelabrutinib) for people with early-stage marginal zone lymphoma who have not yet had treatment. The goal is to see if this medication can control the cancer with fewer side effects than standard treatments.
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
Hear when a new Systemic Lupus Erythematosus, SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.